Thomas M. Wisniewski

Professor, MD
Department of Neurology, Pathology, Psychiatry
New York University
E-mail: thomas.wisniewski@nyumc.org
Page: http://www.med.nyu.edu/biosketch/wisnit01

 

Fields of interest:

Pathogenesis of Alzheimer and prion diseases

 

Recent publications:

Chung E., Ji Y., Sun Y., Kascsak R. J., Kascsak R. B., Mehta P. D., Strittmatter S. M., Wisniewski T.:
Anti-PrPC monoclonal antibody infusion as a novel treatment for cognitive deficits in an Alzheimer's disease model mouse
BMC Neurosci. 2010; 11: 130.

Goni F., Prelli F., Ji Y., Scholtzova H., Yang J., Sun Y., Liang F. X., Kascsak R., Mehta P., Wisniewski T.:
Immunomodulation targeting abnormal protein conformation reduces pathology in a mouse model of Alzheimer's disease
PLoS One 2010; 5(10): e13391.

Wisniewski T., Sigurdsson E. M.:
Murine models of Alzheimer's disease and their use in developing immunotherapies
Biochim. Biophys. Acta 2010; 1802(10): 847-859.

Zhang W., Li Y. S., Nardi M. A., Dang S., Yang J., Ji Y., Li Z., Karpatkin S., Wisniewski T.:
Dissolution of arterial platelet thrombi in vivo with a bifunctional platelet GPIIIa49-66 ligand which specifically targets the platelet thrombus
Blood 2010; 116(13): 2336-2344.

Wegiel J., Kuchna I., Nowicki K., Imaki H., Marchi E., Ma S. Y., Chauhan A., Chauhan V., Bobrowicz T. W., de Leon M., Louis L. A., Cohen I. L., London E., Brown W. T., Wisniewski T.:
The neuropathology of autism: defects of neurogenesis and neuronal migration, and dysplastic changes
Acta Neuropathol. 2010; 119(6): 755-770.

Wisniewski T., Boutajangout A.:
Immunotherapeutic approaches for Alzheimer's disease in transgenic mouse models
Brain Struct. Funct. 2010; 214(2-3): 201-218.

Struthers M., Bett A. J., Wisniewski T., Dubey S. A., Precopio M., Jiang W., Sun Z., Wang H., Nowak I., Putta M. R., Yu D., Tang J. X., Kandimalla E. R., Agrawal S., Casimiro D. R.:
Synthesis and immunological activities of novel agonists of toll-like receptor 9
Cell Immunol. 2010; 263(1): 105-113.

Wisniewski T., Boutajangout A.:
Vaccination as a therapeutic approach to Alzheimer's disease
Mt.SinaiJ. Med. 2010; 77(1): 17-31.

Mosconi L., Mistur R., Switalski R., Tsui W. H., Glodzik L., Li Y., Pirraglia E., De Santi S., Reisberg B., Wisniewski T., de Leon M. J.:
FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's disease
Eur. J. Nucl. Med. Mol. Imaging 2009; 36(5): 811-822.

Sadowski M. J., Pankiewicz J., Prelli F., Scholtzova H., Spinner D. S., Kascsak R. B., Kascsak R. J., Wisniewski T.:
Anti-PrP Mab 6D11 suppresses PrP(Sc) replication in prion infected myeloid precursor line FDC-P1/22L and in the lymphoreticular system in vivo
Neurobiol. Dis. 2009; 34(2): 267-278.